CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. CohBar has assembled the leading position in exploring the mitochondrial genome and its utility for the development of novel therapeutics, including world-renowned expertise in mitochondrial biology, a broad intellectual property estate, key opinion leaders and disciplined drug discovery and development processes. CohBar is utilizing its Mito+ platform to develop modified versions of natural peptides called analogs to treat a variety of serious conditions, with a focus on diseases involving inflammation and fibrosis. The company’s most advanced compound, CB4211, which is under development for the treatment of NASH and obesity, completed a successful Phase 1a/1b clinical trial in August 2021. In addition, CohBar is currently conducting IND-enabling studies for CB5138-3, a peptide with broad anti-fibrotic properties with an initial indication of idiopathic pulmonary fibrosis.